Union Bancaire Privee UBP SA Makes New Investment in Novo Nordisk A/S (NYSE:NVO)

Union Bancaire Privee UBP SA bought a new position in Novo Nordisk A/S (NYSE:NVO) in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund bought 8,842 shares of the company’s stock, valued at approximately $746,000.

Other large investors also recently added to or reduced their stakes in the company. Wealth Enhancement Advisory Services LLC lifted its stake in shares of Novo Nordisk A/S by 14.8% in the third quarter. Wealth Enhancement Advisory Services LLC now owns 289,438 shares of the company’s stock worth $34,463,000 after buying an additional 37,346 shares during the last quarter. Bristlecone Advisors LLC lifted its stake in shares of Novo Nordisk A/S by 7.9% in the third quarter. Bristlecone Advisors LLC now owns 9,898 shares of the company’s stock worth $1,179,000 after buying an additional 725 shares during the last quarter. Clear Harbor Asset Management LLC lifted its stake in shares of Novo Nordisk A/S by 5.0% in the third quarter. Clear Harbor Asset Management LLC now owns 3,628 shares of the company’s stock worth $432,000 after buying an additional 172 shares during the last quarter. Riggs Asset Managment Co. Inc. lifted its stake in shares of Novo Nordisk A/S by 0.9% in the third quarter. Riggs Asset Managment Co. Inc. now owns 44,342 shares of the company’s stock worth $5,280,000 after buying an additional 390 shares during the last quarter. Finally, Cavalier Investments LLC lifted its stake in shares of Novo Nordisk A/S by 6.5% in the third quarter. Cavalier Investments LLC now owns 22,469 shares of the company’s stock worth $2,675,000 after buying an additional 1,380 shares during the last quarter. 11.54% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

A number of brokerages have recently weighed in on NVO. Cantor Fitzgerald restated an “overweight” rating and issued a $160.00 price objective on shares of Novo Nordisk A/S in a research note on Wednesday, November 6th. BNP Paribas upgraded shares of Novo Nordisk A/S to a “strong-buy” rating in a research note on Monday, December 2nd. Sanford C. Bernstein upgraded shares of Novo Nordisk A/S from an “underperform” rating to a “market perform” rating in a research note on Monday, January 6th. Morgan Stanley started coverage on shares of Novo Nordisk A/S in a research note on Wednesday, February 12th. They set an “equal weight” rating for the company. Finally, BMO Capital Markets cut their target price on shares of Novo Nordisk A/S from $156.00 to $105.00 and set an “outperform” rating for the company in a research note on Monday, December 23rd. Two research analysts have rated the stock with a hold rating, six have assigned a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $145.25.

Novo Nordisk A/S Trading Up 2.8 %

Shares of Novo Nordisk A/S stock opened at $90.58 on Tuesday. The firm has a market capitalization of $406.48 billion, a PE ratio of 27.53, a price-to-earnings-growth ratio of 0.90 and a beta of 0.45. The company has a debt-to-equity ratio of 0.62, a current ratio of 0.74 and a quick ratio of 0.55. The company’s fifty day moving average price is $85.66 and its two-hundred day moving average price is $107.72. Novo Nordisk A/S has a 52-week low of $77.82 and a 52-week high of $148.15.

Novo Nordisk A/S (NYSE:NVO) last announced its quarterly earnings results on Wednesday, February 5th. The company reported $0.91 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.88 by $0.03. Novo Nordisk A/S had a net margin of 34.81% and a return on equity of 84.68%. On average, analysts expect that Novo Nordisk A/S will post 3.84 EPS for the current year.

Novo Nordisk A/S Increases Dividend

The firm also recently declared a semi-annual dividend, which will be paid on Tuesday, April 8th. Shareholders of record on Monday, March 31st will be issued a $0.7874 dividend. This represents a yield of 1.2%. The ex-dividend date is Monday, March 31st. This is a positive change from Novo Nordisk A/S’s previous semi-annual dividend of $0.51. Novo Nordisk A/S’s payout ratio is 21.88%.

Novo Nordisk A/S Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.